

**THE MIRENA MIGRAIN: A REVIEW OF THE  
PHARMACODYNAMICS OF LEVONORGESTREL AND  
ITS IMPLICATIONS IN WOMEN'S HEALTH**

**Honors Thesis**

**Presented in Partial Fulfillment of the Requirements  
For the Degree of Bachelor in the Science of Nursing**

In the College of Health and Human Services  
At Salem State University

By  
Lexus D. Earl

Tammi Magazzu, RN, MSN, WHNP-BC  
Faculty Advisor  
Department of Nursing

\*\*\*

The Honors Program  
Salem State University  
2014

## Abstract

The new progestin, levonorgestrel, delivered via an intrauterine system or subdermal implant is showing promising signs of preventing pregnancy, decreasing excessive bleeding with menstruation, and returning fertility when removed (Backman, 2004). As promising as the levonorgestrel parental systems are, side effects are a common cause for concern and are a large reason for premature removal (Coukell & Balfour, 1998). Other than prolonged bleeding from insertion, and heavier periods for some women, other side effects have been observed such as weight gain, mood changes, dizziness and persistent, headache (Backman, 2004). With headache being one of the primary reasons for premature removal, previous literature has shown strong antiestrogenic activity among the pharmacodynamics of levonorgestrel (Schindler, 2003), which in turn may be the causative agent for the headache experienced among users.

Given that headaches are mediated by vasodilation and vasoconstriction, the antiestrogenic activity of levonorgestrel is hypothesized to affect estrogen mediated vasodilation (Schindler, 2003). As one of the strongest antagonist of estrogen, levonorgestrel has also been discussed to affect the oxidation of low-density lipoprotein (LDL) cholesterol impacting the endothelium of the cardiac vasculature (Zhu, Bonet, & Knopp, 2000). This review aims to identify how levonorgestrel could be the causative agent for the physiologic phenomenon of a headache experienced among users so that medical professionals and drug manufacturers can be guided towards developing and prescribing a more effective and tolerable birth control option.

## Table of Contents

	Page
Abstract .....	i
List of Tables .....	iii
Acknowledgements.....	iv
Introduction.....	1
An Overview of the Natural Processes of the Menstrual Cycle_ .....	2
The Impact of Levonorgestrel on the Body .....	4
Menstrual Cycle.....	4
Blood Serum Concentrations and Ovulation .....	5
The Oxidation of LDL-C by LNG and Its Potential Impact on the Cardiovascular System .....	7
Reduction in the Lipid Profile.....	10
LDL-C, LNG-IUD, and the Potential Relationship to Migraines and Headaches.....	11
LDL-C Oxidation and Nitric Oxide Inactivation.....	13
Comparison of the LNG-IUD and the Copper IUD in Headache Frequency and Risk for Atherosclerosis.....	14
Conclusion & Suggestions for: Future Research, Prescribers, and Pharmaceutical Companies ...	16
References.....	18

List of Tables

Table 1: Serum Levels of LNG in Users of the LNG-IUD.....6

Table 2: Lipid Profiles of Users with the LNG IUS and a GnRHa .....9

## Acknowledgements

I would like to acknowledge Professor Tammy Magazzu RN, MSN WHNP-BC and Dr. Victoria Morrison for their support to perform this work.

## Introduction

For many women, the new Levonorgestrel Intrauterine device (LNG-IUD) has alleviated many of the struggles experienced from other forms of birth control. After a one-time insertion, the patient is up to 99.9% protected from pregnancy for up to five years (Backman, 2004). The patient is free from the hassle of remembering to take a pill every day, having to endure an intramuscular injection every three months, or having to worry about the potential failure of barrier methods. By preventing pregnancy for up to five years, the patient is essentially worry-free of an unwanted pregnancy, yet in the desire to get pregnant, the return to fertility after removal is almost immediate (Backman, 2004). In current studies additional benefits of the LNG-IUD include promising signs of protection against intrauterine cancers, endometriosis, dysmenorrhea, and menorrhagia (Backman, 2004). With a supposed low side effect profile, the LNG-IUD is becoming a popular choice for women when choosing a birth control method. While many women report satisfaction with the LNG-IUD, adverse reactions are being looked at to include prolonged bleeding from insertion, heavier periods for some women, in addition to weight gain, mood changes, dizziness and persistent headache (Backman, 2004).

Releasing only 20 mcgs of levonorgestrel (Backman, 2004), it has been noted that of the other hormonal birth control methods that also rely only on levonorgestrel as its birth control hormone (specifically the Norplant levonorgestrel releasing system implanted in the underside of the arm), they have also demonstrated a headache as being a prominent side effect (Coukell & Balfour, 1998). With levonorgestrel being the only hormone involved in these parental devices, this review aims to compare these parental

methods to combination levonorgestrel and estrogen oral contraceptives, and the copper intrauterine device with no hormone involvement. Through comparison, it will be investigated whether the levonorgestrel hormone itself is the causative agent for the headache side effect.

In addition, this review will also look to identify how the pharmacodynamic nature of levonorgestrel could produce a headache based on its antiestrogenic activity. By identifying a possible link between the drug and its role in the headache, the implications for this review are intended to promote healthcare professionals and drug manufacturers to further investigate this particular side effect seeing that it is one of the leading causes of premature removal (Coukell & Balfour, 1998). Given that 60% of LNG-IUD users discontinue this particular birth control method before its five year duration, for unexpected bleeding, pain and discomfort and progestogenic side effects which include a headache (Ewies, 2009), future research is needed for a more tolerable birth control option.

### An Overview of the Natural Processes of the Menstrual Cycle

In the naturally occurring menstrual cycle, estrogen and progesterone are responsible for the endometrial changes necessary to promote ovulation, fertilization, implantation and fetal development. Day 1 of the menstrual cycle is marked by the onset of menses where the endometrial lining is shed, along with the corpus luteum and the unfertilized egg. The hormonal events that trigger menstruation are marked by declining progesterone levels signaled by the decaying corpus luteum and unfertilized egg. Following the decline in progesterone levels, the spiral arterioles and capillaries that

make up the uterine endometrial vasculature begin to degrade resulting in a release of blood into the most superficial epithelium of the endometrium. In an effort to prevent hemorrhage the arterioles contract and constrict. The blood generated from the degradation and contraction of these arterioles further cascade the release of blood from the most superficial endometrial vasculature resulting in menses (Elchalal & Abramov, 1995).

Following menstruation, the proliferative phase (days 7-14) begins as a response to heightened estrogen secretion. Estrogen mediated, regrowth of the endometrial lining occurs; endometrial mucosa thickens, glandular activity increases, and mitotic activity at the basal layer is at an all-time high. The connective tissue of the endometrium known as the stroma becomes more vascular as the constricted and condensed spiral arterioles begin to elongate and re-perfuse the growing endometrial tissue. Nearing ovulation, the endometrium gets thicker, more edematous in response to the heightened perfusion, attracts white blood cells, and macrophages in order to prepare itself for a potential implantation (Elchalal & Abramov, 1995).

Approximately mid-cycle (the 14<sup>th</sup> of a 28 day cycle), estrogen levels reach their maximum prompting a surge of luteinizing hormone (LH) release from the pituitary superseding ovulation. Once ovulation and the release of an egg from the follicle has been achieved, estrogen levels begin to decline and progesterone levels rise. This period marks the luteal phase of the menstrual cycle (Elchalal & Abramov, 1995). From ovulation to approximately 72 hours after, the woman is now fertile and progesterone levels continually rise. Rising progesterone is suggested to suspend the changes and growth of the endometrium to promote implantation and resist overgrowth of the lining.



If fertilization is achieved and implantation occurs, the corpus luteum will persist on the ovary and continue its secretion of progesterone necessary to promote embryonic development and maintenance of the pregnancy. Should fertilization fail, the corpus luteum will degrade triggering the fall of progesterone that will again result in menstruation (Elchalal & Abramov, 1995).

### The Impact of Levonorgestrel on the Body

#### *Menstrual Cycle*

Levonorgestrel is a synthetic second generation progestin designed to mimic the actions of naturally occurring progesterone. Levonorgestrel is successful in preventing pregnancy by thickening the cervical mucosa, suppressing the functioning of the endometrial lining, and working on the pituitary to suppress the LH surge (Coukell & Balfour, 1998). Producing the desired effects that make levonorgestrel successful in preventing pregnancy, there is a change in the woman's natural hormone levels as a result of levonorgestrel exposure. As discussed previously, natural progesterone is responsible for halting the continued growth of the endometrial lining. Progesterone achieves this by suppressing estrogen receptor gene transcription and ultimately estrogen receptor levels (Ewies, 2009). As a result, the endometrial lining is stunted in its growth because of the changes progesterone causes at the estrogen receptor site. Levonorgestrel, again created to mimic natural progesterone, achieves this change in estrogen receptor activity but is sought to be very antiestrogenic in its activity compared to other synthetic progestins (Ewies, 2009). What makes levonorgestrel antiestrogenic is its androgenic effect as an antagonist to estrogen. Natural progesterone and progestins alike directly affect normal

functioning hydroxysteroid dehydrogenase (HSD); HSD-2 is an enzyme whose type 2 form deactivates estrogen ( $E_2$ ) to a weaker form ( $E_1$ ). When progesterone levels are heightened, HSD-2 enzymatic activity increases, churning out more weakened estrogen (Guttinger & Critchley, 2007). The lack of strength in endometrial estrogen is hypothesized to weaken the endometrial blood vessels resulting in the break through bleeding that is experienced by users the first few months after insertion (Guttinger & Critchley, 2007). Keeping in mind that endometrial blood vessels may be affected by this change in estrogen strength, what may be the systemic effects of a weaker estrogen outside the endometrial cavity, under the influence of levonorgestrel? Ovulation for one, mediated by estrogen levels, appears to possibly be affected.

#### *Blood Serum Concentrations and Ovulation*

With the use of the LNG-IUD, it is shown that ovulation is not inhibited in *most* women (Backman, 2004). On the other hand, use of the LNG-IUD produces symptomatology comparable to menopause in 50% of the women treated (Ewies, 2009). Similarly, studies suggest that 50% or more of the users treated with levonorgestrel subdermal devices do not ovulate (Coukell & Balfour, 1998). The difference in ovulatory versus annovulatory cycles in users may lie in the serum levels of levonorgestrel dependent on body weight. In subdermal levonorgestrel devices, for a person weighing >70 kg, serum levonorgestrel levels are decreased by 0.0033 mg/L/kg. In comparison to serum levels of users >70 kg, users who weighed <50 kg had 45% higher serum levels of levonorgestrel (Coukell & Balfour, 1998). Designed to secrete only 20 mcg/day of levonorgestrel continually from a 52 mg reservoir (Selim & Hussein, 2013), if body weight dependent, it may be possible that more than 20 mcg are released in women of

smaller body composition, and some evidence suggests this. Blood serum levels of levonorgestrel is found to vary among users despite alternative research suggesting that serum levels generally stay within 150-200 pg/ml (Guttinger & Critchely, 2007). Alternative studies also suggest that 85% of LNG-IUD users are still ovulatory and that serum levels high enough to inhibit ovulation would require a daily release of at least 50 mcg (Guttinger & Critchely, 2007). If the LNG-IUD releases 50 mcg (2.5 times more than intended at 20 mcg) through simple mathematics we should expect the serum levels to therefore be between 375-500 pg/ml. For comparative assay, the serum levels to which levonorgestrel is suggested to stay, 150-200 pg/ml, is equivalent to 550.65- 734.2 pmol/L. In Table 1, it is apparent that four out of six studies presented in his table show serum levonorgestrel levels reaching higher than 734.2 pmol/L  $\approx$  200 pg/ml. Three of the studies even show levels high enough to inhibit ovulation with serum levonorgestrel

**Table I: Serum Levels of LNG in Users of the LNG-IUD**

The reported steady state serum levels of levonorgestrel in users of LNG-IUS and 30 mg levonorgestrel only pill.  
Study Levonorgestrel serum level (pmol/L)

**Levonorgestrel 30 mg pill**

Weiner et al. [25]                      800

**LNG-IUS**

Ratsula et al. [26]                      455  
Suhonen et al. [27]                      480–640  
Lockhat et al. [9]                        1062  
Nilsson et al. [28]                      640–1601  
Xiao et al. [29]                         960–1601  
Raudaskoski et al. [20]                1504

\*LNG-IUS, Levonorgestrel-releasing Intrauterine System.

Ewies, A. A. (2009). Levonorgestrel-releasing Intrauterine System - The discontinuing story. *Gynecological Endocrinology*, 25(10), 668-673.

Accounting for the variable serum levels, body weight is not the only influential factor. The metabolic rate and clearance rate of levonorgestrel has been found to be very different in users by at least several-fold (Ewies, 2009). Variations in serum levels are suggested to be reflective of the differences in metabolism and responses users may have to levonorgestrel (Ewies, 2009). The pharmacodynamics of levonorgestrel from user to user varies, regardless of whether levonorgestrel is parenteral or enteral in form. This raises the question as to what the impacts are, if any, levonorgestrel could have on the cardiovascular system outside the endometrium of the uterus if serum concentrations are not as expected. Does this have anything to do with the headache experienced among users? Perhaps.

#### Oxidation of LDL-C by Levonorgestrel and Its Potential Impact on Cardiovascular System

Studies suggest that levonorgestrel implants do not significantly affect the lipid profile of users (Sivin, 2003). Research mentions a slight decrease in the total cholesterol level and triglyceride level in the first month of use, with levels returning to baseline shortly thereafter (Sivin, 2003). Given that the serum levels of the LNG-IUD is at its highest in the first month of administration, a decrease in the lipid profile values may not be coincidence. Naturally occurring estrogen has been shown to elicit an antioxidant effect on the lipids circulating throughout the body as it protects low density lipid cholesterol (LDL-C) molecules from being oxidized (Zhu et al., 2000). Oxidized LDL-C has recently been recognized as a contributing factor in the pathogenesis of

atherosclerosis. Oxidation of LDL-C induces the release of inflammatory chemicals by the endothelial walls of the cardiac vasculature, the inhibition of the production of nitric oxide responsible for vasodilation, and the formation of Foam Cells—the distinctive marker of atherosclerosis because their death is what is responsible for the formation of plaques in the arterial walls (Ruiz-Sanz, Navarro, Martínez, Hernández, Matorras, & Ruiz-Larrea, 2007).

In a study done by Zhu et al., 2000, LDL molecules were extracted from the plasma of fasting, healthy donors, not on hormone therapy. Their plasma was then subjected to three progestins: norgestimate, levonorgestrel, medroxyprogesterone acetate (MPA); estrogen, 17 $\beta$ -estradiol (E<sub>2</sub>); and progesterone under oxidation inducing conditions. While 17 $\beta$ -estradiol, showed a protective effect by inhibiting LDL-C oxidation, the progestins were shown to promote its oxidation in a dose-dependent pattern. Estrogen even in combination with the progestins still showed that the progestins inhibited the protective effects of the estrogen. Of all the progestins used in the study, inhibition and enhanced cytotoxicity was greatest with the use of LNG and MPA. This study continues to discuss the importance of LDL oxidation by these two progestins and its importance if not balanced by antioxidants. The consequences include the development of vascular conditions including atherosclerosis, vasospasm, and activity of arterial protein kinase C activity (a molecule that plays a role in irritating the blood vessels causing vasospasm, constriction and potential chronic contraction of the arteries [Laher & Zhang, 2001]), (Zhu et al., 2000). While it is known that levonorgestrel lacks the protective antioxidant structures found in estrogen, it is not known why or what in the levonorgestrel hormone molecule promotes LDL-C oxidation (Zhu et al., 2000).

Another review promotes that the LNG-IUD can be used in women who have a cardiac history of embolisms, it decreases the resistance of activated protein C activity (a marker for inflammation), and cites one study in which Asian women using the LNG-IUD saw a small decrease in their total cholesterol profiles (Mansour, 2012). In another study done in 2010, 44 women with endometriosis were comparatively treated with the LNG-IUD and a GnRH analogue (GnRHa) while their lipid levels in conjunction with other cardiac markers were monitored (Ferreira, Vieira, Rosa-e-Silva, Sá Rosa-e-Silva, Nogueira& Ferriani, 2010). While the subjects activated protein C (APC) decreased, concurrent with the previously mentioned study, there was also a significant decrease in their lipid profiles. Table 2, shows that the results demonstrate a significant decrease in total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol after six months.

**Table 2: Lipid Profiles of Users with the LNG IUS and a GnRHa**

(Data are reported as means±SD; □ p<.05 compared to pretreatment; T p<.05 for comparison of posttreatment results.)

	<b>LNG-IUS (n=22)</b>		<b>GnRHa (n=18)</b>	
	Basal	6 months	Basal	6 months
<b>TC (mg/dL)</b>	242.3±82.2	180.8±31.6□τ	228.6±57.7	223.5±58.4τ
<b>TG (mg/dL)</b>	115.3±75.8	85.5±41.2□τ	128.9±91.4	149.2±76.9τ
<b>LDL-C (mg/dL)</b>	158.7±65	115.6±25.3□τ	142.7±40	138.9±42.8τ
<b>HDL-C (mg/dL)</b>	60.5±19.3	47.9±10.8□	60±15.6	54.7±16.6

Ferreira, R., Vieira, C., Rosa-e-Silva, J., Sá Rosa-e-Silva, A. J., Nogueira, A. A., & Ferriani, R. A. (2010). Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. *Contraception*, 81(2), 117-122.

*Reduction in the Lipid Profile*

Given that the LNG-IUD is often prescribed for women with endometriosis, it is difficult to discern what is actually happening to cause the decreases seen in the lipid profile. The liver is most likely participatory in the removal of the cholesterol from the body, but does some of it oxidize? When evaluating the greatest decrease in the separate lipid levels themselves (TG, LDL, HDL) in this particular study, LDL-C levels decreased the most with an average decrease of 43.1 mg/dL. In addition to LDL-C reduction, unfavorable decreases were seen in the HDL cholesterol levels, adding to the perceived cardiovascular risk of the LNG-IUD because of HDL cholesterol's importance in protection against heart disease (Ferreira et al., 2010). This study suggests that the decrease in LDL-C is favorable for the LNG-IUD user because with less LDL-C circulating there is less to be oxidized (Ferreira et al., 2010), however the risk of it being oxidized, if it is in fact being oxidized, is heightened due to the lack of antioxidant protection of estrogen because of its antagonism by levonorgestrel.

While this particular study had a small sample size, it raises importance questions and concerns. Is there perhaps something in the pathogenesis of endometriosis that may cause the body to respond to levonorgestrel in this particular way? Or does this suggest a phenomenon such as lipid oxidation as discussed prior which will increase cardiovascular risk for any user? And lastly, is this phenomenon only occurring in some but not all women? While more research is needed to identify and answer these questions, this particular study discusses the variability of the lipid profile in users of the LNG-IUD seen in other research (Ferreira et al., 2010). Citing six different studies, this article discusses that a decrease is seen in all aspects of the lipid profile among normal women (without

uterine and menstrual abnormalities); citing another study, this article discusses that in normal women HDL and TC levels decreased with no mentionable decreases in TG or LDL levels; and citing three other studies, these particular articles mention that no changes in lipid profiles were observed, and that even an increase in HDL cholesterol can occur (Ferreira et al., 2010). With such variability in lipid levels among users, it would come as no surprise if there was perhaps a relation to the variability in the serum levels seen in users with the LNG-IUD.

#### LDL-C, LNG-IUD, and the Potential Relationship to Migraines and Headaches

In the United States, 43% of women are affected by migraines with the prevalence of migraines increasing with age (Edlow & Bartz, 2010). Most studies that investigate the reasons for discontinuing the use of the LNG-IUD or other parental levonorgestrel implants use *headache* as a category. However, most have not broken this category down into the specific types of headaches (i.e. tension, migraine, cluster, etc.) that are occurring (Coukell & Balfour, 1998; Daud & Ewies, 2008). The LNG-IUD is contraindicated in those who have migraines to begin with (Willet, 2009), and in the informational packet that is distributed with the LNG-IUD it is suggested that the user go immediately to their doctor if they experience an increase in persistent headaches or a migraine for the first time (Willet, 2009). Considering this, perhaps there is a causal relationship not yet understood.

In the New Drug Application submitted to the FDA in 2009 for the Mirena® LNG-IUD, the medical officer's additive comment stated that a headache as one of the



top three non-serious adverse events, is *possibly* related the LNG-IUD (Willett, 2009). In one study presented in the application, a list of treatment-emergent adverse events were reported with headache being the most prevalent adverse event with 13% of 80 subjects experiencing a headache. In comparison to medroxyprogesterone acetate (MPA), a third generation progestin with similar antiestrogenic effects but to a slightly lesser extent (Zhu et al., 2000), only 9% of 82 subjects experienced a headache (Willett, 2009). While there seems to be an absence of literature to my knowledge, concluding whether or not the prevalence of headache is associated with the strength of the antiestrogenic activity of the progestins used in progestin-only birth control methods, its possibility should not be overlooked.

Given that evidence that levonorgestrel has been seen to promote oxidation of LDL-C, it might not be coincidence that the results and by products of LDL-C oxidation could contribute to a headache or a migraine considering vasospasm, and the release of inflammatory chemicals occur with LDL-C oxidation. Diagnosis of migraines in clinical practice relies on a throbbing pain as the major symptom of migraine headaches (Edlow & Bartz, 2010). However in recent literature, a migraine is no longer suspected to be due to vascular condition (Gruber, Bernecker, Pailer, Lechner, Horejsi, Möller, & Truschnig-Wilders, 2010). Instead, it is supposedly a neurological condition in nature with vascular complications, especially ischemic stroke (Gruber et al., 2010). LDL-C oxidation is an independent risk factor for atherogenesis because of its molecular strength and its ability to cause vascular dysfunctions through the production of free-radical oxygen formation, tissue remodeling, and induction of oxidative stress on the body. In the pathophysiology behind migraines, there is strong evidence that oxidative stress plays a role in their

development (Gruber et al., 2010). In two studies, LDL-C was significantly increased in those who experienced migraines regardless of BMI (Gruber et al., 2010; Bernecker, Pailer, Kieslinger, Horejsi, Möller, Lechner, & Gruber, 2011). Given that LDL-C oxidation is an independent risk factor for cardiovascular complications including migraines, the risk of developing atherogenic and harmful cardiovascular changes in the body may perhaps still be present even in the absence or improved atherogenic profile from use of the LNG-IUD.

#### *LDL-C Oxidation and Nitric Oxide Inactivation*

While it is not known how levonorgestrel promotes LDL-C oxidation, it is interesting to note that oxidative stress impacts the beneficial effects of nitric oxide (NO) (Bernecker et al., 2011), a chemical also partly mediated by estrogen. NO is responsible for: inhibiting platelet function, inhibiting the aggregation of inflammatory cells, promoting enzymatic fibrinolysis of clots, weakening endothelial smooth muscle proliferation, and vasodilation (Bernecker et al., 2011). Estrogen stimulates the production of nitric oxide by stimulating neuronal nitric oxide synthase (nNOS) which impacts the nervous system. This in turn produces and impacts endothelial nitric oxide synthase (eNOS) production in the cardiovascular system (Lekontseva, Chakrabarti, Jiang, Cheung, & Davidge, 2011). Given that migraines are both neuronal and vascular in nature, perhaps changes in serum estrogen or its strength is the link to the female migraine and the reason why migraine occurrence is three times higher in post-pubertal females compared to males (Edlow & Bartz, 2010). Not only is estrogen protective against atherogenesis, it also promotes regrowth of damaged endothelium, regulates pain

perception and regulates endothelial muscle tone (Ashkenazi & Silberstein, 2006).

Estrogen receptors are also found in both cardiac cells and vascular cells (Tarhouni, Guihot, Freidja, Toutain, Henrion, Baufreton, & Henrion, 2013).

It is not known whether or not the antiestrogenic activity of the levonorgestrel molecule impacts the nitric oxide production that estrogen regulates because of its antagonism. Nor is it known whether or not the impact of levonorgestrel on the HSD-2 enzymatic activity producing a weaker estrogen is responsible for many of the pro-oxidant activities in the body in conjunction to a change in NO production. Keeping in mind that the products of LDL-C oxidation known to be caused by levonorgestrel can inactivate NO (Bernecker et al., 2011), produce inflammatory chemicals, and cause vasospasm, levonorgestrel very well may be the causative agent for the headache or migraine developed or exacerbated in users as the FDA's medical officer suggested, and carry a potential cardiac risk as well.

#### Comparison of the LNG-IUD and the Copper IUD in Headache Frequency and Risk for Atherosclerosis

Because migraines with and without aura (a visual and auditory component to symptoms) can contribute to ischemic strokes, the World Health Organization has rated each birth control category for clinical practice either a category 1, 2, 3, 4 in regard to headaches. While the copper IUD has been rated a category 1, meaning that there are no contraindications for a specific condition or set of conditions [headache] that would otherwise raise alarm, the LNG-IUD and other progestin only birth control methods (IUD, IM injections, pills) are given a category 2 (Harris & Kaneshiro, 2009). Category 2

indicates that the particular birth control method can be used; however, careful observation of the patient must occur. Although the progestin only methods are ranked higher, in order to begin to assess and possibly single out levonorgestrel as the cause of the headache developed among many users, more research needs to be conducted. Most literature suggests variability in the lipid profiles among LNG-IUD users. When comparing lipid profiles of the LNG-IUD against those in users of the Copper-IUD, there is no significant difference in the lipid profile (Ng, Liang, & Singh, 2009) or the occurrence of headaches (Suhonen, Haukkamaa, Jakobsson, & Rauramo, 2004). While studies suggest that a favorable lipid profile is being seen among users of both the Copper-IUD and the LNG-IUD, regardless of the number of circulating lipid molecules in the blood, it is the size of lipid molecules that is an important factor in the development of atherosclerosis, not necessarily the number (Ruiz-Sanz et al., 2007). In lieu, despite having a favorable profile, it is not favorable if oxidation is occurring and it is not being detected because research is only looking at the number and not the size of the LDL-C molecules. The consensus is that individuals with small, dense LDL-C molecules are more at risk for the development of atherosclerosis, and that those with large LDL-C molecules are found in those who are healthy with a normal BMI (Manning, Edwards, Wagner, Wagner, Adams, & Parks, 1997).

However, in an interesting study done on *Cynomolgus* Monkeys who were fed an atherogenic diet, and subject to estrogen (EE) alone, EE+LNG in combination, and LNG alone, it was demonstrated that exogenous hormones affect LDL-C size and density (Manning et al., 1997). Although treatment with EE and EE+LNG resulted in smaller, more dense, LDL-C molecules, the molecules contained less cholesterol, less

apolipoprotein E (a molecule responsible for carrying cholesterol in the bloodstream), and reacted less with arterial proteoglycans (the molecule that LDL-C and apolipoprotein E fuses to in the arteries to form plaques) (Manning et al., 1997). LNG alone, although producing a larger LDL-C molecule, reacted more with the arterial proteoglycans. The authors of this study suggested that in women, smaller LDL-C molecules do not increase their risk for the development of atherosclerosis (Manning et al., 1997). More recent literature suggests the opposite, in that smaller LDL-C molecules are subject to oxidation more so than larger LDL molecules (Ruiz-Sanz et al., 2007).

Not only does LNG induce LDL-C oxidation, but interestingly enough copper does as well, and is one of the substances used to promote LDL-C oxidation in laboratory testing (Chiang, Parthasarathy, & Santanam, 2004). Is it coincidence then that both substances show almost equal lipid profiles and headache frequencies in users? Perhaps not.

#### Conclusion & Suggestions for: Future Research, Prescribers, and Pharmaceutical Companies

Considering that neither birth control method contains any estrogen, more research needs to be conducted to find out whether slow atherogenic changes are occurring and whether a headache is an indicator. When assessing whether these atherogenic changes are occurring, research needs to focus on LDL-C size instead of number. Although a decrease in the lipid profile is favorable, if there are any atherogenic changes occurring regardless, the user has a right to know, and the provider should be aware of it and forewarn his/her patients. The provider should also take the complaint of

a headache as an indication that something more serious may be occurring and consider the removal of the LNG-IUD. While the LNG-IUD is still a very good and beneficial birth control for many, there is still room for improvement. Given that LNG is one of the most pro-oxidative progestins available, and that the amount of hormone released from the LNG-IUD reservoir is variable and dependent on BMI, metabolic rate, and individual clearance rate (Ewies, 2009), in order to reduce atherogenic risk in users, perhaps a less pro-oxidative progestin IUD can be used, with different doses of the hormone available based on weight.

The doses available should correspond not only to the patient's weight, but also to the patient's condition(s), if any, that would also warrant the placement of an IUD. For instance, if there is a cancer present in the endometrium, higher doses of the progestin IUD, or the LNG-IUD would be prescribed as long as the benefits outweigh the risks. In healthy premenopausal women of normal BMI, the lowest dose of the progestin IUD should be prescribed. The hormone and its dosage should be enough to protect against pregnancy, dysmenorrhea, and menorrhagia, but should not exceed the total amount of circulating estrogen. While there are less pro-oxidative progestins available, there still may be a small risk of contribution to atherosclerosis, however, as long as estrogen is available to exert its antioxidant effect, it can help combat its development. More research would need to be conducted on which progestin achieves the same benefits as the LNG-IUD, but with a lesser risk of contribution to atherosclerosis. By using a different progestin, it may provide for a better, more tolerable birth control option that is tailored to the user, thereby contributing to the minimization of the progestogenic side

effects and a headache that is experienced among many users and a reason for premature removal.

## References

- Ashkenazi, A., & Silberstein, S. D. (2006). Hormone-related headache: pathophysiology and treatment. *CNS Drugs*, *20*(2), 125-141.
- Backman, T. (2004). Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. *Drug Safety*, *27*(15), 1185-1204.
- Bernecker, C. C., Pailer, S. S., Kieslinger, P. P., Horejsi, R. R., Möller, R. R., Lechner, A. A., & Gruber, H. J. (2011). Increased matrix metalloproteinase activity is associated with migraine and migraine-related metabolic dysfunctions. *European Journal of Neurology*, *18*(4), 571-576. doi:10.1111/j.1468-1331.2010.03205.x
- Chiang, K., Parthasarathy, S., & Santanam, N. (2004). Estrogen, neutrophils and oxidation. *Life Sciences*, *75*(20), 2425-2438.
- Coukell, A. J., & Balfour, J. A. (1998). Levonorgestrel subdermal implants: a review of contraceptive efficacy and acceptability. *Drugs*, *55*(6), 861-887.
- Daud, S., & Ewies, A. (2008). Levonorgestrel-releasing intrauterine system: why do some women dislike it? *Gynecological Endocrinology: The Official Journal Of The International Society Of Gynecological Endocrinology*, *24*(12), 686-690. doi:10.1080/09513590802444167
- Edlow, A., & Bartz, D. (2010). Hormonal contraceptive options for women with headache: a review of the evidence. *Reviews In Obstetrics And Gynecology*, *3*(2), 55-65.
- Elchalal, U., Abramov Y. (1995). Uterine biology and the intrauterine device. *Advanced Drug Delivery Reviews*, *17*, 151-164.



- Ewies, A. A. (2009). Levonorgestrel-releasing intrauterine system—the discontinuing story. *Gynecological Endocrinology*, *25*(10), 668-673.  
doi:10.1080/09513590903159656
- Ferreira, R., Vieira, C., Rosa-e-Silva, J., Sá Rosa-e-Silva, A. J., Nogueira, A. A., & Ferriani, R. A. (2010). Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. *Contraception*, *81*(2), 117-122.  
doi:10.1016/j.contraception.2009.08.003
- Gruber, H. J., Bernecker, C. C., Pailer, S. S., Lechner, A. A., Horejsi, R. R., Möller, R. R., & Truschnig-Wilders, M. M. (2010). Lipid profile in normal weight migraineurs—evidence for cardiovascular risk. *European Journal of Neurology*, *17*(3), 419-425. doi:10.1111/j.1468-1331.2009.02861.x
- Harris, M., & Kaneshiro, B. (2009). An evidence-based approach to hormonal contraception and headaches. *Contraception*, *80*(5), 417-421.
- Laher, I., Zhang, J. (2001). Protein kinase C and cerebral vasospasm. *Journal of Cerebral Blood Flow and Metabolism*, *21*, 887–90.
- Lekontseva, O., Chakrabarti, S., Jiang, Y., Cheung, C., & Davidge, S. (2011). Role of neuronal nitric-oxide synthase in estrogen-induced relaxation in rat resistance arteries. *The Journal of Pharmacology and Experimental Therapeutics*, *339*(2), 367-375. doi:10.1124/jpet.111.183798
- Manning, J. M., Edwards, I. J., Wagner, W. D., Wagner, J. D., Adams, M. R., & Parks, J. S. (1997). Effects of contraceptive estrogen and progestin on the atherogenic

potential of plasma LDLs in cynomolgus monkeys. *Arteriosclerosis Thrombosis and Vascular Biology*, 17(7), 1216-1223.

Mansour, D. (2012). The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception. *Contraception*, 85(3), 224-234.

doi:10.1016/j.contraception.2011.08.003

Ng, Y., Liang, S., & Singh, K. (2009). Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism—a randomized comparative study. *Contraception*, 79(1), 24-28.

doi:10.1016/j.contraception.2008.07.012

Ruiz-Sanz, J., Navarro, R., Martínez, R., Hernández, M., Matorras, R., & Ruiz-Larrea, M. (2007). No effect of menstrual cycle on LDL oxidizability and particle size.

*Maturitas*, 57(3), 253-260. doi:10.1016/j.maturitas.2007.01.008

Schindler, A. E. (2003). Differential effects of progestins on hemostasis. *Maturitas*,

46(S31). doi:10.1016/j.maturitas.2003.09.016

Selim, M., & Hussein, A. (2013). Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS). *Contraception*, 87(4), 396-403.

doi:10.1016/j.contraception.2012.12.008

Sivin, I. (2003). Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. *Drug Safety*, 26(5), 303-335.

Suhonen, S., Haukkamaa, M., Jakobsson, T., & Rauramo, I. (2004). Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. *Contraception*, 69(5), 407.

doi:10.1016/j.contraception.2003.11.008

Tarhouni, K., Guihot, A., Freidja, M., Toutain, B., Henrion, B., Baufreton, C., & ...

Henrion, D. (2013). Key role of estrogens and endothelial estrogen receptor  $\alpha$  in blood flow-mediated remodeling of resistance arteries. *Arteriosclerosis, Thrombosis, And Vascular Biology*, 33(3), 605-611.

doi:10.1161/ATVBAHA.112.300334

Willet, G. U.S. Food and Drug Administration. (2009). *Clinical Review* (NDA 21-225 [SE1- Applicant submission 027]). Washington, D.C.

Zhu, X., Bonet, B., & Knopp, R. (2000). Estradiol 17beta inhibition of LDL oxidation and endothelial cell cytotoxicity is opposed by progestins to different degrees. *Atherosclerosis*, 148(1), 31-41.